|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/22 | |
| A61P 11/00 | |||
| A61P 29/00 | |||
| A61P 1/04 | |||
| A61P 43/00 |
| (11) | Number of the document | 3256150 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16714558.0 |
| Date of filing the European patent application | 2016-02-04 | |
| (97) | Date of publication of the European application | 2017-12-20 |
| (45) | Date of publication and mention of the grant of the patent | 2020-12-09 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IT2016/000027 |
| Date | 2016-02-04 |
| (87) | Number | WO 2016/129005 |
| Date | 2016-08-18 |
| (30) | Number | Date | Country code |
| RM20150056 | 2015-02-09 | IT | |
| UB20153089 | 2015-09-18 | IT |
| (72) |
ROMANI, Luigina, IT
GARACI, Enrico, IT
|
| (73) |
SciClone Pharmaceuticals International Ltd.,
PO Box 309 Ugland House, Grand Cayman KY-1-1104,
KY
|
| (54) | THYMOSIN ALPHA 1 FOR USE IN TREATMENT OF CYSTIC FIBROSIS |
| THYMOSIN ALPHA 1 FOR USE IN TREATMENT OF CYSTIC FIBROSIS |